NCT00146614View on ClinicalTrials.gov

Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2003

Conditions
Graft Versus Host DiseaseHematologic Malignancies
Interventions
DRUG

Sirolimus

DRUG

Tacrolimus

DRUG

Methotrexate

PROCEDURE

Stem Cell Transplantation

Trial Locations (3)

02115

Beth Isreal Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00146614 - Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation | Biotech Hunter | Biotech Hunter